MaveriX Oncology Profiled in Nature Biopharma Dealmakers

The September 2022 special issue of Nature Biopharma Dealmakers focused on innovative biotech companies in the field of immuno-oncology. Co-targeting cancer and TIME with conditionally activated small molecule therapeutics

MaveriX Oncology Profiled in Nature Biopharma Dealmakers

The September 2022 special issue of Nature Biopharma Dealmakers focused on innovative biotech companies in the field of immuno-oncology. Co-targeting cancer and TIME with conditionally activated small molecule therapeutics